The BioPlex 2200 Lyme Total assay detects Lyme disease at every stage of infection. Engineered to target Total (IgG/IgM) antibodies to Borrelia burgdorferi, this screening assay is an effective solution for laboratories to provide accurate information about patients' Lyme disease status.
Contact a Bio-Rad sales representative today.
Highly sensitive for acute, convalescent, and late stages of infection, so patients can be more confident in the accuracy of their Lyme screen results.
The BioPlex 2200 Lyme Total assay was designed to include multiple Lyme disease targets expressed in the earliest stages of Lyme infection.
Sensitivity data is from the CDC LSR Premarketing Panel and does not imply an endorsement by the CDC.
Lyme disease can be contracted anywhere - on vacation or even in your own backyard.
The BioPlex 2200 Lyme Total assay can inform people if they have contracted Lyme, regardless of where they were exposed to the disease.
The BioPlex 2200 Lyme Total assay identifies more specific targets to Lyme disease by leveraging a modified VlsE antigen which reduces cross-reactivity and improves specificity.
Raymond Dattwyler, M.D. describing how his lab's work was used by Bio-Rad to create the BioPlex 2200 Lyme Total assay
The BioPlex 2200 Lyme Total assay was tested against a CDC panel of "look-alike diseases" known to cross-react in other Lyme disease testing assays.
The BioPlex 2200 Lyme Total assay showed low cross-reactivity and is unlikely to report a positive Lyme result if a patient is actually infected with a disease tested in this panel.
Specificity data is from the CDC LSR Premarketing Panel and does not imply an endorsement by the CDC.
The BioPlex 2200 Lyme Total assay was compared with three top-selling competitor Lyme disease screening assays using the CDC LSR Premarketing Panel of well-characterized Lyme disease samples.
in 3 disease stages
*Material not sufficient to test
**Overall sensitivity calculated with an assumed 100% late sensitivity
against look-alike diseases and healthy controls
The BioPlex 2200 Lyme Total assay is highly engineered to detect IgG and IgM antibodies to Borrelia burgdorferi in human serum or plasma for all stages of Lyme disease.
3 Beads Detect 4 Different Targets
By leveraging Bio-Rad's multiplexed technology, the BioPlex 2200 Lyme Total assay is able to detect multiple Lyme disease targets - resulting in a greater number of opportunities to detect Lyme disease in a patient's sample. All of our targets were selected for their ability to identify patients early in their Lyme disease infection. The modified FVlsE was added to also identify patients in the later stages of infection.
Integrated quality assurance with two internal QC beads
*The BioPlex 2200 Total Lyme assay is only available in the U.S. and Canada